[
    {
        "initiator": "Alzheimer's Disease",
        "resolution_description": "\"Integrating the innovative computational approach of quantum computing with the practical applications of induced pluripotent stem cells (iPSCs) could revolutionize our understanding and treatment of Alzheimer's Disease. By employing quantum computing to model and predict the intricate interactions of neurotransmitters and genetic mutations, alongside developing patient-specific iPSC models to study neuronal interactions and disease mechanisms, we can create a comprehensive strategy that advances research and treatment beyond the prevailing amyloid hypothesis.\"",
        "new_actor": "Quantum Neurogenesis Modeler",
        "participants": [],
        "required_participants": [
            {
                "participant": "Фармакологические компании",
                "reasoning": "Фармакологические компании are essential for translating research findings into viable therapies. Their involvement will help in developing drugs based on the insights gained from quantum computing models and ensuring that these therapies reach the market."
            },
            {
                "participant": "3D iPSC-based organoids",
                "reasoning": "3D iPSC-based organoids allow for the study of Alzheimer's Disease in a more physiologically relevant context. These models can help test hypotheses generated by quantum computing simulations and provide a platform for drug testing and development."
            }
        ],
        "recruited_sources": [
            "Pharmaceutical Companies",
            "Medical Research Institutions",
            "Neurodegeneration",
            "Healthcare Systems"
        ],
        "agreement_structure": {
            "recruited_sources": [
                "Neurodegeneration",
                "Healthcare Systems",
                "Medical Research Institutions",
                "Pharmaceutical Companies"
            ]
        }
    },
    {
        "initiator": "Tau protein",
        "resolution_description": "Initiator: Tau Protein, Resolution: \"Revolutionize the understanding and treatment of Alzheimer's Disease by developing targeted therapies that stabilize tau protein structures, using bioengineered molecular scaffolds to prevent their pathological aggregation and restore normal cellular function, thereby shifting the focus from amyloid-centric approaches to a tau-centric paradigm.\"",
        "new_actor": "Actor: Tau Therapeutics Innovator",
        "participants": [],
        "required_participants": [
            {
                "participant": "Фармакологические компании",
                "reasoning": "Pharmaceutical companies play a key role in the development and commercialization of new therapies. Their involvement is essential for translating research findings into viable treatments that stabilize tau proteins and address Alzheimer's Disease."
            },
            {
                "participant": "3D iPSC-based organoids",
                "reasoning": "3D iPSC-based organoids can provide an innovative platform for studying tau protein dynamics in a controlled environment. They can aid in the screening of potential therapies and understanding the mechanisms of tau aggregation and stability."
            }
        ],
        "recruited_sources": [
            "Neurons",
            "Microtubules",
            "Neurodegenerative Diseases"
        ],
        "agreement_structure": {
            "recruited_sources": [
                "Microtubules",
                "Neurons",
                "Neurodegenerative Diseases"
            ]
        }
    },
    {
        "initiator": "APOE ɛ4",
        "resolution_description": "\"APOE ɛ4 could transform Alzheimer's understanding and treatment by pioneering an epigenetic reprogramming approach to modulate gene expression patterns specifically associated with APOE ɛ4 alleles, thereby targeting the root genetic predispositions and altering disease progression at its core.\"",
        "new_actor": "Epigenetic Reprogrammer for APOE ɛ4",
        "participants": [],
        "required_participants": [
            {
                "participant": "Фармакологические компании",
                "reasoning": "Pharmaceutical companies are essential for translating the epigenetic reprogramming strategies into viable treatments. Their involvement will provide the necessary resources and infrastructure for drug development and clinical trials."
            },
            {
                "participant": "induced pluripotent stem cells (iPSCs)",
                "reasoning": "Induced pluripotent stem cells (iPSCs) are vital for modeling the effects of APOE ɛ4 and testing the epigenetic reprogramming methods. They allow for the creation of patient-specific models that can elucidate disease mechanisms and therapeutic responses."
            },
            {
                "participant": "Blood-brain barrier (BBB)",
                "reasoning": "Understanding the blood-brain barrier (BBB) is critical for ensuring that any therapeutic strategies developed can effectively reach the brain. This knowledge will help in designing treatments that can successfully cross the BBB and exert their effects on Alzheimer's pathology."
            }
        ],
        "status": "COLLAPSED"
    },
    {
        "initiator": "iPSCs",
        "resolution_description": "\"Induced pluripotent stem cells (iPSCs) could revolutionize the understanding and treatment of Alzheimer's Disease by creating patient-specific neural models that unveil personalized disease mechanisms and enable the discovery of tailored regenerative therapies, bypassing traditional hypotheses and focusing on individual cellular pathology.\"",
        "new_actor": "Actor Name: Personalized Neural Model Innovator (PNMI)",
        "participants": [],
        "required_participants": [
            {
                "participant": "Фармакологические компании",
                "reasoning": "Pharmaceutical companies are crucial for translating the findings from iPSC research into regenerative therapies and for funding clinical trials that could lead to new treatments for Alzheimer's Disease."
            },
            {
                "participant": "Пациенты",
                "reasoning": "Patients provide the necessary perspective and biological samples needed for creating patient-specific iPSC models, ensuring that the research is relevant and personalized to actual disease conditions."
            },
            {
                "participant": "induced pluripotent stem cells (iPSCs)",
                "reasoning": "Induced pluripotent stem cells (iPSCs) are the core of the proposed resolution, as they enable the generation of patient-specific neural models critical for understanding Alzheimer's Disease and developing tailored therapies."
            }
        ],
        "status": "COLLAPSED"
    }
]